

Orhan Aktas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3363252/publications.pdf>

Version: 2024-02-01

219
papers

16,320
citations

17440

63
h-index

18130

120
g-index

223
all docs

223
docs citations

223
times ranked

14788
citing authors

#	ARTICLE	IF	CITATIONS
1	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 280.	7.2	686
2	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. <i>Journal of Neuroinflammation</i> , 2012, 9, 14.	7.2	593
3	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16.	3.6	494
4	Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress. <i>Cell</i> , 2010, 142, 613-624.	28.9	482
5	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	13.7	433
6	Sirt1 contributes critically to the redox-dependent fate of neural progenitors. <i>Nature Cell Biology</i> , 2008, 10, 385-394.	10.3	412
7	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology, The</i> , 2017, 16, 797-812.	10.2	397
8	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. <i>Journal of Neuroinflammation</i> , 2016, 13, 279.	7.2	351
9	The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. <i>Trends in Neurosciences</i> , 2006, 29, 518-527.	8.6	329
10	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	5.3	315
11	Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF- κ B Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2004, 173, 5794-5800.	0.8	314
12	Characteristics of Susac syndrome: a review of all reported cases. <i>Nature Reviews Neurology</i> , 2013, 9, 307-316.	10.1	293
13	Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 239.	4.5	276
14	Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin. <i>Journal of Experimental Medicine</i> , 2003, 197, 725-733.	8.5	271
15	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , 2016, 15, 574-584.	10.2	266
16	Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. <i>FASEB Journal</i> , 2005, 19, 1347-1349.	0.5	261
17	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021, 20, 762-772.	10.2	261
18	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1005-1015.	1.9	228

#	ARTICLE	IF	CITATIONS
19	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 282.	7.2	217
20	Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL. <i>Neuron</i> , 2005, 46, 421-432.	8.1	211
21	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 189-199.	10.2	210
22	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 756.	9.0	206
23	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. <i>Journal of Neuroinflammation</i> , 2016, 13, 281.	7.2	202
24	TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. <i>Lancet</i> , The, 2003, 361, 2036-2043.	13.7	194
25	Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. <i>Brain</i> , 2004, 127, 111-119.	7.6	194
26	Neuronal Damage in Brain Inflammation. <i>Archives of Neurology</i> , 2007, 64, 185.	4.5	193
27	Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6650-6655.	7.1	193
28	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. <i>PLoS Medicine</i> , 2007, 4, e133.	8.4	187
29	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1287-1295.	1.9	184
30	Apheresis therapies for NMOSD attacks. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e504.	6.0	173
31	Fingolimod is a potential novel therapy for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010, 6, 373-382.	10.1	165
32	Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Annals of Neurology</i> , 2009, 66, 310-322.	5.3	151
33	Optical Coherence Tomography in Parkinsonian Syndromes. <i>PLoS ONE</i> , 2012, 7, e34891.	2.5	145
34	Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1887-1895.	3.0	141
35	Racial differences in neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2018, 91, e2089-e2099.	1.1	140
36	Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation. <i>Journal of Experimental Medicine</i> , 2003, 198, 1729-1740.	8.5	137

#	ARTICLE	IF	CITATIONS
37	Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue. <i>Journal of Neuroscience</i> , 2004, 24, 2458-2464.	3.6	134
38	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	1.9	123
39	The complex world of oligodendroglial differentiation inhibitors. <i>Annals of Neurology</i> , 2011, 69, 602-618.	5.3	119
40	Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. <i>Nature Medicine</i> , 2009, 15, 788-793.	30.7	118
41	Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica. <i>JAMA Neurology</i> , 2013, 70, 390.	9.0	112
42	Retinal Damage in Multiple Sclerosis Disease Subtypes Measured by High-Resolution Optical Coherence Tomography. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-10.	0.8	111
43	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2008, 3, e1928.	2.5	110
44	Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1422-1429.	3.0	108
45	Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand But Presence of Its Receptors in the Human Brain. <i>Journal of Neuroscience</i> , 2002, 22, RC209-RC209.	3.6	106
46	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	6.0	104
47	Worldwide Incidence and Prevalence of Neuromyelitis Optica. <i>Neurology</i> , 2021, 96, 59-77.	1.1	101
48	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. <i>Journal of Neuroinflammation</i> , 2014, 11, 46.	7.2	100
49	Autoregulation of Th1-mediated inflammation by <i>twist1</i> . <i>Journal of Experimental Medicine</i> , 2008, 205, 1889-1901.	8.5	96
50	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.1	96
51	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019, 92, e48-e54.	1.1	95
52	Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 22-34.	3.0	92
53	Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. <i>Trends in Neurosciences</i> , 2010, 33, 140-152.	8.6	89
54	IFN γ secreted by microglia mediates clearance of myelin debris in CNS autoimmunity. <i>Acta Neuropathologica Communications</i> , 2015, 3, 20.	5.2	89

#	ARTICLE	IF	CITATIONS
55	Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. <i>Clinical Immunology</i> , 2012, 142, 15-24.	3.2	88
56	Frequency of blood CX3CR1 ⁺ positive natural killer cells correlates with disease activity in multiple sclerosis patients. <i>FASEB Journal</i> , 2005, 19, 1902-1904.	0.5	85
57	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 261.	7.2	84
58	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. <i>Journal of Neuroinflammation</i> , 2022, 19, 19.	7.2	82
59	Cytotoxic CD8 ⁺ T Cell-Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death. <i>Journal of Neuroscience</i> , 2009, 29, 15397-15409.	3.6	78
60	Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20057-20062.	7.1	77
61	Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation. <i>PLoS ONE</i> , 2011, 6, e25456.	2.5	75
62	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	5.3	72
63	Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 43-55.	3.7	71
64	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	65
65	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	64
66	Placebo-controlled study in neuromyelitis optica- Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.0	63
67	TRAIL limits excessive host immune responses in bacterial meningitis. <i>Journal of Clinical Investigation</i> , 2007, 117, 2004-2013.	8.2	62
68	The role of TRAIL/TRAIL receptors in central nervous system pathology. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 2912.	3.0	61
69	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. <i>Brain</i> , 2013, 136, 1778-1782.	7.6	60
70	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	3.0	60
71	Atorvastatin Induces T Cell Anergy via Phosphorylation of ERK1. <i>Journal of Immunology</i> , 2005, 174, 5630-5635.	0.8	59
72	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 815.	9.0	59

#	ARTICLE	IF	CITATIONS
73	Subtle retinal pathology in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 290-297.	3.7	57
74	Impact of HMG-CoA reductase inhibition on brain pathology. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 342-349.	8.7	56
75	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2017, 264, 1370-1380.	3.6	55
76	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. <i>Journal of Neurology</i> , 2016, 263, 575-582.	3.6	53
77	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	6.0	53
78	Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS. <i>PLoS ONE</i> , 2012, 7, e38741.	2.5	52
79	Modulation of adult hippocampal neurogenesis during myelin-directed autoimmune neuroinflammation. <i>Glia</i> , 2011, 59, 132-142.	4.9	51
80	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , 2015, 85, 610-618.	1.1	50
81	Altered fovea in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	50
82	Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. <i>Multiple Sclerosis Journal</i> , 2004, 10, 182-187.	3.0	48
83	Premature aging of the hippocampal neurogenic niche in adult Bmal1-deficient mice. <i>Aging</i> , 2015, 7, 435-449.	3.1	48
84	Neuromyelitis optica following human papillomavirus vaccination. <i>Neurology</i> , 2012, 79, 285-287.	1.1	47
85	Visual evoked potentials in neuromyelitis optica and its spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2014, 20, 617-620.	3.0	47
86	Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. <i>Journal of Neurology</i> , 2015, 262, 1379-1384.	3.6	47
87	Retinal Optical Coherence Tomography in Neuromyelitis Optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	47
88	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial study protocol. <i>BMJ Open</i> , 2016, 6, e010956.	1.9	46
89	Systemic IFN- β treatment induces apoptosis of peripheral immune cells in MS patients. <i>Journal of Neuroimmunology</i> , 2003, 137, 187-196.	2.3	44
90	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	7.2	44

#	ARTICLE	IF	CITATIONS
91	Anti-CD20 therapies and pregnancy in neuroimmunologic disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	43
92	Retinal Neurodegeneration in Wilson's Disease Revealed by Spectral Domain Optical Coherence Tomography. <i>PLoS ONE</i> , 2012, 7, e49825.	2.5	43
93	Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. <i>Journal of Neuroimmunology</i> , 2007, 184, 17-26.	2.3	42
94	Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. <i>Journal of Neuroimmunology</i> , 2001, 114, 160-167.	2.3	41
95	Beyond blood brain barrier breakdown – in vivo detection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI. <i>Journal of Neuroinflammation</i> , 2009, 6, 20.	7.2	41
96	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	41
97	Development of oral cladribine for the treatment of multiple sclerosis. <i>Journal of Neurology</i> , 2010, 257, 163-170.	3.6	40
98	Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 199-204.	3.6	40
99	Immunoproteasomes Are Important for Proteostasis in Immune Responses. <i>Cell</i> , 2013, 152, 935-937.	28.9	39
100	Death Ligands and Autoimmune Demyelination. <i>Neuroscientist</i> , 2006, 12, 305-316.	3.5	38
101	Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2016, 13, 47-57.	4.4	38
102	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. <i>CNS Drugs</i> , 2018, 32, 1159-1171.	5.9	38
103	Redox-regulated fate of neural stem progenitor cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 1543-1554.	2.4	37
104	Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e363.	6.0	37
105	Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. <i>Journal of Neuroinflammation</i> , 2018, 15, 71.	7.2	37
106	Targeting B Cells to Modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	37
107	Interferon β -1a and β -1b for patients with multiple sclerosis: updates to current knowledge. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 137-153.	3.0	36
108	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020, 94, e407-e418.	1.1	36

#	ARTICLE	IF	CITATIONS
109	Genome-wide significant association of ANKRD55rs6859219 and multiple sclerosis risk. <i>Journal of Medical Genetics</i> , 2013, 50, 140-143.	3.2	34
110	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015, 52, 848-855.	3.2	34
111	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987158.	1.0	34
112	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. <i>Glia</i> , 2017, 65, 1521-1534.	4.9	33
113	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	3.7	33
114	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change. <i>Current Opinion in Neurology</i> , 2019, 32, 327-337.	3.6	32
115	COVID-19 and management of neuroimmunological disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 347-348.	10.1	32
116	Elevated Bcl-XL levels correlate with T cell survival in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 126, 213-220.	2.3	31
117	Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29,000 subjects: Figure 1. <i>Journal of Medical Genetics</i> , 2012, 49, 558-562.	3.2	31
118	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	8.4	31
119	Thinking outside the box: non-canonical targets in multiple sclerosis. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 578-600.	46.4	31
120	Targeting B cells to modify MS, NMOSD, and MOGAD. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	30
121	Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. <i>BMC Infectious Diseases</i> , 2015, 15, 61.	2.9	29
122	BAX inhibitor-1 is a Ca ²⁺ channel critically important for immune cell function and survival. <i>Cell Death and Differentiation</i> , 2016, 23, 358-368.	11.2	29
123	Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. <i>Journal of Neurology</i> , 2019, 266, 1421-1428.	3.6	29
124	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	7.6	29
125	Immune regulation of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 3-14.	1.8	28
126	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2019, 16, 203.	7.2	28

#	ARTICLE	IF	CITATIONS
127	Misdiagnoses and delay of diagnoses in Moyamoya angiopathy—a large Caucasian case series. <i>Journal of Neurology</i> , 2019, 266, 1153-1159.	3.6	28
128	Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. <i>Lancet Neurology</i> , The, 2011, 10, 293-295.	10.2	27
129	p57kip2 regulates glial fate decision in adult neural stem cells. <i>Development (Cambridge)</i> , 2012, 139, 3306-3315.	2.5	27
130	Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. <i>Journal of Neurochemistry</i> , 2018, 146, 86-98.	3.9	26
131	Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004, 149, 195-201.	2.3	25
132	Serum neurofilament light chain. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	25
133	Induction of Apoptosis of CD4+ T Cells by Immunomodulatory Therapy of Multiple Sclerosis with Glatiramer Acetate. <i>European Neurology</i> , 2003, 50, 200-206.	1.4	24
134	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. <i>Journal of Neuroinflammation</i> , 2014, 11, 129.	7.2	24
135	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. <i>Neurology</i> , 2015, 85, 521-527.	1.1	24
136	Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion. <i>Experimental Brain Research</i> , 2007, 178, 542-553.	1.5	23
137	Bleak prospects for primary progressive multiple sclerosis therapy: Downs and downs, but a glimmer of hope. <i>Annals of Neurology</i> , 2009, 66, 429-432.	5.3	23
138	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016, 13, 278.	7.2	23
139	Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy. <i>Current Pharmaceutical Design</i> , 2003, 9, 245-256.	1.9	23
140	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019, 326, 19-27.	2.3	22
141	Independent replication of STAT3 association with multiple sclerosis risk in a large German case-control sample. <i>Neurogenetics</i> , 2012, 13, 83-86.	1.4	21
142	Interferon-Î2-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. <i>BMC Neurology</i> , 2014, 14, 247.	1.8	21
143	Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. <i>Neuroscience Letters</i> , 2019, 704, 116-125.	2.1	21
144	Monoclonal Antibodies for Multiple Sclerosis: An Update. <i>BioDrugs</i> , 2019, 33, 61-78.	4.6	21

#	ARTICLE	IF	CITATIONS
145	Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 479-484.	2.0	20
146	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
147	Longitudinal Retinal Changes in <scp>MOGAD</scp>. Annals of Neurology, 2022, 92, 476-485.	5.3	20
148	Assessment of microRNA-related SNP effects in the 3â€² untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics, 2014, 15, 129-134.	1.4	19
149	Predictors of response to opicinumab in acute optic neuritis. Annals of Clinical and Translational Neurology, 2018, 5, 1154-1162.	3.7	19
150	Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Multiple Sclerosis Journal, 2018, 24, 1776-1778.	3.0	18
151	Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Safety, 2019, 42, 633-647.	3.2	18
152	Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years â€œ case report. BMC Neurology, 2020, 20, 158.	1.8	18
153	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC Neurology, 2019, 19, 190.	1.8	17
154	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 978-985.	1.9	17
155	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	16
156	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. Journal of Neuroimmunology, 2021, 360, 577699.	2.3	16
157	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356.	2.0	16
158	Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurology, The, 2021, 20, 991-1000.	10.2	16
159	Functional reorganization is a maladaptive response to injury â€œ NO. Multiple Sclerosis Journal, 2017, 23, 193-194.	3.0	15
160	Revised diagnostic criteria for neuromyelitis opticaâ€œ” incorporation of NMO-IgG status. Nature Clinical Practice Neurology, 2007, 3, E1-E1.	2.5	15
161	Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. Clinical Neurophysiology, 2015, 126, 2040-2041.	1.5	14
162	Relapse-independent multiple sclerosis progression under natalizumab. Brain Communications, 2021, 3, fcb229.	3.3	14

#	ARTICLE	IF	CITATIONS
163	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. <i>Neurology</i> , 2022, 98, .	1.1	14
164	Cladribine as a therapeutic option in multiple sclerosis. <i>Clinical Immunology</i> , 2012, 142, 68-75.	3.2	13
165	Photoreceptor layer thinning in Parkinsonian syndromes. <i>Movement Disorders</i> , 2014, 29, 1222-1223.	3.9	13
166	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016, 6, 2073-2079.	1.8	13
167	Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. <i>Molecular Neurodegeneration</i> , 2016, 11, 53.	10.8	13
168	Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma. <i>European Journal of Paediatric Neurology</i> , 2017, 21, 661-665.	1.6	13
169	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	1.9	13
170	Electrostatically stabilized magnetic nanoparticles – an optimized protocol to label murine T cells for in vivo MRI. <i>Frontiers in Neurology</i> , 2011, 2, 72.	2.4	12
171	Drug Treatment of Clinically Isolated Syndrome. <i>CNS Drugs</i> , 2019, 33, 659-676.	5.9	12
172	Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	12
173	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 909-914.	3.7	11
174	Long-term adherence and response to botulinum toxin in different indications. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 15-28.	3.7	11
175	Pain, depression, and quality of life in adults with MOG-antibody-associated disease. <i>European Journal of Neurology</i> , 2021, 28, 1645-1658.	3.3	11
176	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.0	11
177	Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 406-408.	2.0	10
178	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	1.9	10
179	Old and new breakthroughs in neuromyelitis optica. <i>Lancet Neurology</i> , The, 2020, 19, 280-281.	10.2	10
180	Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 243-243.	1.9	9

#	ARTICLE	IF	CITATIONS
181	Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. <i>BMJ Open Ophthalmology</i> , 2016, 1, e000008.	1.6	9
182	Meningitis gone viral: description of the echovirus wave 2013 in Germany. <i>BMC Infectious Diseases</i> , 2019, 19, 1010.	2.9	8
183	Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects. <i>Current Opinion in Neurology</i> , 2019, 32, 346-357.	3.6	8
184	Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany. <i>Clinical Neurology and Neurosurgery</i> , 2020, 197, 106142.	1.4	8
185	Oral therapies for multiple sclerosis: are we there yet?. <i>Lancet Neurology</i> , The, 2010, 9, 454-457.	10.2	7
186	Alterations of the outer retina in non-arteritic anterior ischaemic optic neuropathy detected using spectral-domain optical coherence tomography. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 496-508.	2.6	7
187	Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 952-961.	3.7	7
188	Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. <i>Journal of Neurology</i> , 2009, 256, 1906-1908.	3.6	6
189	Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 63.	3.7	6
190	Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 290-295.	2.1	6
191	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 782.	2.4	6
192	Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism. <i>Redox Biology</i> , 2022, 49, 102221.	9.0	6
193	The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis. <i>Brain Stimulation</i> , 2022, 15, 403-413.	1.6	6
194	Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells – implications for multiple sclerosis This work was supported by grants from the DFG, the Hertie-Stiftung and the DMSG.1. <i>Journal of Neuroimmunology</i> , 2000, 103, 69-75.	2.3	4
195	Is It Too Early to Predict the Failure of Natalizumab in NMO? – Reply. <i>Archives of Neurology</i> , 2012, 69, 1085.	4.5	4
196	Natalizumab in clinical practice: managing the risks, enjoying the benefits. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1181-1181.	1.9	4
197	CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .	6.0	4
198	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. <i>Frontiers in Immunology</i> , 2021, 12, 794075.	4.8	4

#	ARTICLE	IF	CITATIONS
199	Shifting borders, crossing boundaries: The case of combined central and peripheral demyelination. <i>Multiple Sclerosis Journal</i> , 2018, 24, 550-551.	3.0	3
200	No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. <i>Frontiers in Neurology</i> , 2019, 10, 741.	2.4	3
201	CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography. <i>Annals of Neurology</i> , 2019, 85, 615-617.	5.3	3
202	Retinal Changes After Posterior Cerebral Artery Infarctions Display Different Patterns of the Nasal und Temporal Sector in a Case Series. <i>Frontiers in Neurology</i> , 2020, 11, 508.	2.4	3
203	Case Report: Persisting Lymphopenia During Neuropsychiatric Tumor Multiple Sclerosis Rebound Upon Fingolimod Withdrawal. <i>Frontiers in Neurology</i> , 2021, 12, 785180.	2.4	3
204	Beyond axonal transection: Hippocampal damage in multiple sclerosis. <i>Annals of Neurology</i> , 2011, 69, 433-436.	5.3	2
205	Fulminant intramedullary spinal cord sarcoidosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 47-48.	2.0	2
206	Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients. <i>BMC Neurology</i> , 2020, 20, 333.	1.8	2
207	Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019, 93, 767-768.	1.1	2
208	Capillary microscopy in Europeans with idiopathic Moyamoya angiopathy. <i>Microcirculation</i> , 2020, 27, e12616.	1.8	1
209	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. <i>Cells</i> , 2020, 9, 175.	4.1	1
210	Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue. <i>Frontiers in Neurology</i> , 2021, 12, 696807.	2.4	1
211	Multiple Sklerose – weit mehr als eine Entmarkungskrankheit. <i>E-Neuroforum</i> , 2004, 10, 188-194.	0.1	0
212	New aspects regarding mechanisms of tissue damage in the course of autoimmune demyelination. <i>Signal Transduction</i> , 2005, 5, 245-249.	0.4	0
213	Long-term adherence and subjective treatment effect of botulinum toxin in different neurologic diseases. <i>Toxicon</i> , 2018, 156, S67-S68.	1.6	0
214	Occipital repetitive transcranial magnetic stimulation does not affect multifocal visual evoked potentials. <i>BMC Neuroscience</i> , 2020, 21, 48.	1.9	0
215	Ein Paradigmenwechsel und die Zukunft. , 2013, , 189-196.		0
216	Neue, experimentelle und zukünftige Therapieansätze. , 2015, , 361-368.		0

#	ARTICLE	IF	CITATIONS
217	Neue, experimentelle und zukünftige Therapieansätze. , 2018, , 353-359.		0
218	Author response: Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology, 2020, 95, 610-610.	1.1	0
219	Therapie der multiplen Sklerose: Medikamentöse Ansätze zur Remyelinisierung in Präfung. , 0, , .		0